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PURPOSE. To investigate the relationship between vascular
function parameters measured at the retinal and systemic level
and known markers for cardiovascular risk in patients with
impaired glucose tolerance (IGT).
METHODS. Sixty age- and sex-matched white European adults
(30 with IGT and 30 with normal glucose tolerance [NGT])
were recruited for the study. Fasting plasma glucose, lipids, and
24-hour blood pressure (BP) were measured in all subjects.
Systemic vascular and endothelial function was assessed by
using carotid-artery intimal media thickness (cIMT) and flow-
mediated dilation (FMD). Retinal vascular reactivity was
assessed by the dynamic retinal vessel analyzer. Additionally,
blood glutathione (reduced glutathione [GSH], glutathione
disulfide [GSSG], and total glutathione [tGSH]) and plasma von
Willebrand (vWF) factor levels were also measured.
RESULTS. Individuals with IGT demonstrated higher BP values (P
< 0.001), fasting triglyceride (TG) levels and TG:high-density
lipoprotein (HDL) ratios (P < 0.001) than NGT subjects.
Furthermore, total:HDL-cholesterol (HDL-C) ratios and Fra-
mingham scores were raised (P ¼ 0.010 and P < 0.001,
respectively). Blood glutathione levels (GSH, GSSG, and tGSH)
were lower (P < 0.001, P¼0.039, and P < 0.001, respectively)
while plasma vWF was increased (P ¼ 0.014) in IGT subjects
compared to controls. IGT individuals also demonstrated
higher IMT in right and left carotid arteries (P ¼ 0.017 and P
¼ 0.005, respectively) alongside larger brachial artery diameter
(P¼0.015) and lower FMD percentage (P¼0.026) and glyceryl
trinitrate–induced dilation (P¼0.012) than healthy controls. At
the retinal arterial level, the IGT subjects showed higher
baseline diameter fluctuations (BDFs) (P ¼ 0.026), longer
reaction time (RT) (P¼ 0.032), and reduced baseline-corrected
flicker response (bFR) (P¼ 0.045). In IGT subjects, retinal BDF
correlated with total:HDL (P ¼ 0.003) and HDL-C (P¼ 0.004).
Arterial RT also correlated with FMD (P¼0.017) in IGT but not
NGT subjects.
CONCLUSIONS. In IGT individuals there is a relationship between
macro- and microvascular function, as well as a direct
correlation between the observed retinal microcirculatory
changes and established plasma markers for cardiovascular
diseases. Multifactorial preventive interventions to decrease
vascular risk in these individuals should be considered. (Invest
Ophthalmol Vis Sci. 2012;53:5102–5108) DOI:10.1167/
iovs.12-9512
Impaired glucose tolerance (IGT) refers to an intermediatemetabolic state between normal and diabetic state and is
characterized by insulin resistance and impairment in insulin
secretion. It is predicted that the numbers of those diagnosed
with IGT worldwide will rise from 200 million at present to
400 million by the year 2030.1 A proportion (5%–12%) of those
diagnosed with IGT will progress to type 2 diabetes mellitus
(T2DM) each year, therefore representing a major cause of
public health concern. IGT is also associated with a high risk of
cardiovascular disease (CVD),2 and this, along with being a
transition stage towards T2DM, qualifies this condition as a
disease state.3 Consequently, close follow-up of individuals
suffering from IGT, and early identification of vascular
dysfunction, could represent an important step in prevention
of future cardiovascular morbidities.
Recent evidence suggests that endothelial dysfunction, an
early pathophysiologic stage in the development of T2DM and/
or CVD, can be detected very early in subjects at risk, often
before the manifestation of carbohydrate intolerance. Indeed,
IGT subjects have been shown to demonstrate both systemic
macrovascular endothelial dysfunction and functional changes
in the microvasculature similar to those observed in patients
with early T2DM.4,5 This latter observation is particularly
important owing to supporting evidence suggesting that the
microvasculature is an early target for systemic diseases such as
T2DM. Consequently, measurements that identify early chang-
es at this level could potentially be used as predictors of local
or systemic vascular complications.6
Dynamic retinal vessel analysis, a noninvasive technique
that assesses retinal vascular responses to flickering light, has
been shown to identify early signs of vascular dysfunction in
individuals with various degrees of risk for CVD even in the
absence of overt clinical disease.7,8 Indeed, by using this
technique, we have demonstrated that young, healthy individ-
uals with a genetic predisposition towards diabetes exhibit
early signs of impaired retinal dilatory responses.7
Previous research has shown early abnormal microvascular
vasodilation alongside macrovascular changes in individuals at
risk for T2DM.9 However, a correlation between micro- and
macrovascular reactivity measures is found only when the
study groups (controls, relatives of T2DM patients, IGT
individuals, and T2DM patients) are grouped together. Conse-
quently, as no other studies have addressed this issue, to date
there is still very little knowledge about simultaneous vascular
function changes at both the micro- and macrocirculation level
and their importance in individuals with other predisposing
risk factors for T2DM, such as IGT. Therefore, the aim of this
study was to investigate the relationship between vascular
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function parameters measured at the retinal and systemic level
and known markers for CVD risk in patients with IGT.
METHODS
Study Sample
White European subjects aged 35 to 55 years were recruited through a
nurse-led community oral glucose tolerance test (OGTT) clinic within
the Birmingham East and North National Health Service (NHS) Trust,
Birmingham, United Kingdom, from October 2010 to April 2011.
Subjects were referred by their primary care physician for suspected
glucose metabolism issues (i.e., suspected T2DM or IGT). A 75-g OGTT
was carried out as per World Health Organization protocol and a
diagnosis of IGT was confirmed by a consultant diabetologist.10 All IGT
subjects were considered ‘‘patient-na¨ıve,’’ as they were unaware of the
IGT diagnosis at the time of the OGTT. The investigator (S.R.P.) was
masked from the OGTT, and thus there was no bias in patient selection,
that is, only selecting ‘‘high-risk’’ subjects. In addition, age-matched
normoglycemic controls (also confirmed after OGTT) were recruited
through promotion of the study at the Aston University Health Clinics,
Birmingham, United Kingdom.
Subjects were excluded if they had a positive diagnosis or were
taking medication for cardio- or cerebrovascular disease, coronary
artery disease, heart failure, arrhythmia, stroke, transient ischemic
attacks, peripheral vascular disease, hypertension, severe dyslipidemia
(defined as plasma TG >6.00 mM or cholesterol levels >7.00 mM), and
diabetes or were smokers (including ex-smokers). All subjects taking
vasoactive substances, including dietary/vitamin/antioxidant supple-
mentation and bronchodilators, were not included in the present study.
In addition, subjects were also excluded if they had a refractive error of
more than 63 diopter spheres and more than 61 diopter cylindrical
equivalent, an intraocular pressure (IOP) of more than 24 mm Hg,
cataract, or any other media opacities that either prevent retinal
vascular examination or undermine the quality of data, as well as if they
had a history of intraocular surgery or any form of retinal or neuro-
ophthalmic disease affecting the ocular vascular system.
Written informed consent was obtained from all participants and
ethical approval was sought from local and NHS ethical committees.
The study was designed and conducted in accordance with the tenets
of the Declaration of Helsinki.
Investigations
All the participants underwent a routine ophthalmologic assessment
and standardized anthropometric measurements for height and weight
(used to calculate body mass index [BMI]¼weight/height2) as well as
waist and hip measurements (used to calculate waist to hip ratio).
Female participants were asked to fill in a validated menstrual cycle
questionnaire and their investigations were carried out during the first
week of the menstrual cycle (follicular phase) as per previously
established protocol.11,12
Blood Sampling and Analyses
General Assessment for CVD Risk. All participants were asked
to fast and refrain from caffeine, alcohol, chocolate, and carbonated
drinks and to not exercise for 12 hours before the date of the study. All
blood samples were obtained by a qualified phlebotomist in the
morning, between 9 AM and 10 AM. Fasting plasma glucose, TG, total
cholesterol, and HDL-C were measured by using standard routine
laboratory techniques with the Reflotron Desktop Analyzer (Roche
Diagnostics, UK). The TG:HDL-C ratio, a measure of endothelial
function, and the Framingham score as a means of cardiovascular risk
for a 10-year period,13 were also determined from the above values.
Oxidative Stress Markers. Fasted blood was collected and initial
processing was carried out within 10 minutes of blood collection. Each
sample was then processed and analyzed for reduced glutathione
(GSH), glutathione disulfide (GSSG), and total glutathione (tGSH),
according to previous protocols.14
Vascular Endothelial Cell Function Markers.
Von Willebrand Factor (vWF) Assay. Fasted blood was collected by
venepuncture and processed for further batch analysis by enzyme-
linked immunosorbent assay according to an established protocol.15
Ambulatory Blood Pressure (BP) Measurements
Systemic BP was measured by using a 24-hour computer-operated
ambulatory BP monitor (Cardiotens-01; Meditech Ltd., Hungary) for
each subject. Mean arterial pressure (MAP), as a means of describing
cardiac output function in relation to arteriolar resistance, was
calculated by using the following equation: MAP » (2 =3 3 DBP) þ
(1
=
33 SBP) with the pulse pressure (PP) parameter equation: PP¼ SBP –
DBP, where SBP is systolic BP and DBP is diastolic BP.
Intima-Media Thickness (IMT) Assessment
High-resolution B-mode ultrasound system (Acuson Sequoia, 5-MHz
linear transducer; Siemens) was used to obtain longitudinal images of
the right and left extracranial far wall of the common carotid artery
(CCA). The images were evaluated by using ultrasonographic frames of
the CCA as previously recommended.16 In each carotid segment, far-
wall IMT was measured bilaterally for a single CCA view. Each IMT
measure, also used for statistical analysis, represented an average of
three to five measurement points.
Vascular Function Studies
Retinal vessel reactivity was measured with the dynamic retinal vessel
analyzer (DVA, IMEDOS; GmbH, Jena, Germany) by using an already
established and recommended protocol.17,18 All measurements were
performed in one randomly selected eye for each subject, between
8:00 and 11:00 AM in a quiet, temperature-controlled room (228C).
Following full-pupil dilation with tropicamide 1% (Minims; Chauvin
Pharmaceuticals Ltd., UK), a region of interest encompassing vessel
segments of approximately 500 lm was chosen. Retinal vessel
reactivity, in the form of arterial and venous reaction time (RT) and
maximum diameter (MD), were determined with our newly defined
method of sequential and diameter response analysis (SDRA), which is
described elsewhere.19 In short, SDRA tries to overcome what were
considered as shortfalls of the DVA software algorithms and focuses on
time and diameter responses for each flicker response as opposed to an
averaged response. Furthermore, the fluctuations in baseline diameter
are taken into account, thus providing further insight into reaction
patterns as a possible tool for the assessment of vessel physiology.19
The following retinal vessel reactivity and time course parameters were
calculated: baseline diameter fluctuation (BDF) as the difference
between maximum and minimum baseline vessel diameter; the MD
as the maximal vessel dilation in response to flicker light stimulation
expressed as a percentage from baseline; the MD reaction time (MDRT)
as the time taken (seconds) to reach the maximum vessel diameter
during 20-second flicker exposure; the maximum constriction (MC) as
the percentage to baseline minimal vessel diameter within 30 seconds
of the recovery period; and the maximum constriction reaction time
(MCRT) as the time taken (seconds) to reach maximal vessel
constriction. In addition, the dilation amplitude, as the difference
between maximal dilation and constriction responses and the baseline-
corrected flicker response (bFR), which accounted for the BDF, were
also computed.
Brachial artery flow-mediated dilation (FMD) was measured by
using high-resolution color Doppler imaging ultrasonography, with a 7-
mm 8-MHz linear-array (Acuson Sequoia; Siemens, UK), and the
diameter was continuously measured by using wall-detection special-
ized artificial neural networking software (VIA Software, UK) from the
anterior to the posterior interface between the media and adventitia on
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a personal computer. The procedure was carried out to a previously
validated and universally accepted protocol of 2 minutes baseline,
followed by 5 minutes occlusion and 2 minutes recovery. Following 10
minutes of reacclimatization, an exogenous nitric oxide donor (300
mcg sublingual glyceryl trinitrate [GTN] tablet) was administered. The
FMD percentage was determined as absolute change from baseline, as
well as GTN-induced changes, and a ratio of both of these values was
then determined.20
Power Calculation and Statistical Analysis
From previous studies, a change of 30% with an SD of 2.5% in retinal
vessel reactivity has been shown to be significant.21,22 Additionally,
FMD studies have shown a 20% reduction with an SD of 1.85% in FMD
response in those with IGT.23 As the study design was multifactorial in
nature, it was calculated that n ¼ 25 was sufficient to provide 90%
power with an a of 0.05. Furthermore, the sensitivity and reproduc-
ibility of the techniques in healthy subjects have been reported
previously.12,24
All analyses were performed with Statistica software (version 9;
StatSoft Inc., Tulsa, OK). Before all analysis, data were tested for normal
distribution and thus a suitable test was adopted. Differences in mean
values for each of the measured variables were compared by
independent samples t-test (or Wilcoxon) for continuous variables. A
multivariate analysis was performed to investigate possible influences
of parameters such as age, sex, BMI, BP, and circulating biomarkers
(such as glucose, TG, cholesterol, vWF, and glutathione levels) on the
measured variables. Comparison of retinal vessel reactivity for each
flicker period was made by repeated measures (or Friedman) analysis
of variance (ANOVA) following within-group analysis. Differences
between groups in retinal and systemic vascular function were
computed by analysis of covariance (ANCOVA) where applicable. A P
value of <0.05 was considered statistically significant, unless stricter
criteria were adopted for within-group and multivariate analysis (P 
0.01 to account for multiple comparisons and thereby minimize bias
towards type II errors).
RESULTS
An initial 100 individuals were screened at a nurse-led clinic,
and following OGTT and confirmed IGT diagnosis, 40 were
excluded as they did not meet the inclusion criteria (pre-
existing comorbidity and/or taking vasoactive medication; 20
diagnosed with T2DM, 10 with cardiovascular issues, and 10
presenting with gestational diabetes mellitus). Finally, 30 White
European IGT subjects (15 men and 15 women) and 30 normal
glucose tolerance (NGT) subjects (15 men and 15 women)
were recruited for the final protocol.
The baseline characteristics of both groups are presented in
Table 1. There were no significant differences in age, IOP, and
cholesterol levels (HDL, low-density lipoprotein [LDL], and
total cholesterol) between IGT subjects and controls. However,
compared to healthy age- and sex- matched NGT controls, the
IGT group had significantly higher 24-hour SBP, DBP, MAP, and
PP values (P ¼ 0.001, P ¼ 0.017, P ¼ 0.004, and P ¼ 0.023,
respectively), alongside raised fasting levels of glucose and TG
(P < 0.001). TG:HDL-C and total:HDL-C ratios, as well as
Framingham scores, were also significantly higher in those
with IGT (P < 0.001, P ¼ 0.010, and P < 0.001, respectively)
than in NGT healthy controls. Those with IGT showed greater
right- (P ¼ 0.017) and left-side (P ¼ 0.005) carotid artery IMT
than their normoglycemic counterparts.
IGT subjects had lower blood GSH (P < 0.001), GSSG (P¼
0.039), and tGSH (P < 0.001), as well as higher plasma vWF
levels (P ¼ 0.014), than the NGT subjects (Table 2). The
average retinal arterial BDF (P¼ 0.026) and MDRT (P¼ 0.032)
were higher and bFR was lower (P¼ 0.045) in IGT individuals
than in NGT subjects (Table 3). Figures 1 and 2 show the
individual three flicker cycle responses and relevant significant
P values for MDRT (flicker cycle 1, P¼ 0.011; and flicker cycle
2, P ¼ 0.022) and bFR (flicker cycle 2, P ¼ 0.014). Multiple
regression analyses showed significant correlations between
vWF and arterial RT (P ¼ 0.029) only; therefore, the P values
quoted were calculated with ANCOVA correcting for these
significant confounding variables.
In addition, a multivariate analysis showed significant and
positive correlations between retinal arterial BDF and to-
tal:HDL (r ¼ 0.541; P ¼ 0.003), as well as negative correlation
TABLE 1. Baseline Demographic and Metabolic Data of Both Groups
NGT (n ¼ 30) IGT (n ¼ 30) P Value
Demographic data 15 M:15 F 15 M:15 F
Age, y 47.7 6 10 47.7 6 10.2 -
Weight, kg 75.6 6 14.7 80.2 6 14.6 0.127
BMI, kg/m2 26.0 6 4.22 27.6 6 5.33 0.092
WHR 0.93 6 0.11 0.97 6 0.05 0.075
SBP, mm Hg 118 6 12 127 6 18* 0.001
DBP, mm Hg 75 6 8 80 6 11* 0.010
MAP, mm Hg 89 6 10 96 6 13* 0.004
PP, mm Hg 43 6 10 47 6 10* 0.010
IOP, mm Hg 14 6 3 15 6 2 0.090
Metabolic data
Fasting glucose, mM 4.84 6 0.69 5.46 6 0.84* <0.001
2-h GTT, mM 6.06 6 1.03 9.81 6 2.09* <0.001
TG, mM 1.20 6 0.51 1.76 6 1.02* <0.001
HDL-C, mM 1.21 6 0.38 1.08 6 0.40 0.120
LDL cholesterol, mM 2.65 6 0.77 2.67 6 1.03 0.883
Total cholesterol, mM 4.39 6 0.82 4.56 6 1.06 0.372
TG:HDL-C, mM 2.59 6 1.62 4.81 6 4.36* <0.001
CVD risk data
Total:HDL-C, mM 3.98 6 1.33 4.78 6 2.17* 0.010
R-IMT, mm 0.055 6 0.015 0.065 6 0.015* 0.010
L-IMT, mm 0.057 6 0.017 0.069 6 0.016* 0.005
Framingham score 1.9 6 2.8 4.5 6 5.8* <0.001
Values quoted in mean 6 SD. GTT, glucose tolerance test; L-IMT,
left intima media thickness; R-IMT, right intima media thickness; WHR,
waist to hip ratio.
* Significant differences indicated in bold as P  0.01.
TABLE 2. Plasma Markers for Oxidative Stress and Endothelial Function in Both Groups
NGT (n ¼ 30) IGT (n ¼ 30) P Value
GSH, lM 934.33 (407.15–1293.81) 536.09 (300.19–688.52)* <0.001
GSSG, lM 98.11 (40.93–117.27) 64.53 (26.84–68.40)* 0.039
GSH:GSSG 15.25 (5.37–21.95) 13.05 (6.05–18.83) 0.311
tGSH, lM 1130.54 (592.74–1634.95) 665.15 (399.48–761.24)* <0.001
vWF, l/dL 122.3 6 54.9 149.8 6 59.2* 0.014
* Significant differences indicated in bold as P < 0.05.
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with HDL-C (r ¼ 0.522; P ¼ 0.004) (Fig. 3). Furthermore,
retinal arterial MDRT correlated negatively with brachial artery
FMD (r ¼ 0.4546, P ¼ 0.017) in the IGT but not the NGT
group (Fig. 4).
No significant correlations were found between the
measured blood glutathione levels (GSH, GSSG, tGSH, and
GSH:GSSG) and retinal vascular reactivity parameters (all P >
0.05).
An ANCOVA analysis revealed that the IGT group showed a
larger brachial artery diameter (P ¼ 0.015) but lower FMD
percentage than the control group (P ¼ 0.026). Furthermore,
the GTN-induced dilation was lower (P ¼ 0.012) and the
FMD:GID ratio was higher (P¼ 0.034) in the IGT group than in
healthy controls (Table 4).
DISCUSSION
The results of our pilot study suggest that IGT individuals
demonstrate signs of early vascular dysfunction as measured by
functional (at macro- and microcirculatory levels) and circula-
tory markers. Moreover, in addition to a relationship between
functional macro- and microvascular parameters, there appears
to be a direct correlation between the observed retinal
microcirculatory changes and established plasma markers for
CVD risk.
Consistent with previous research,25,26 individuals with IGT
recruited for this present study presented with high BP levels
as well as increased markers of systemic endothelial dysfunc-
tion (impaired FMD response and increased vWF). They also
demonstrated high levels of dyslipidemia (higher TG levels and
cholesterol ratios) and Framingham risk scores. All these
factors are well known to contribute towards CVD risk in
prediabetes.27 In particular, dyslipidemia results in a reduced
nitric oxide (NO) availability, possibly through generation of
reactive oxygen species (ROS) that act to quench NO.28
Indeed, in line with previous research,29 our IGT group also
showed reduced levels of blood glutathione levels (in reduced
and oxidized forms) when compared to the NGT group. This
observation, in association with the observed abnormal lipid
metabolism, could be used to explain, to some extent, the
observed presence of endothelial dysfunction at multiple levels
in our IGT group.30 The relationship between circulatory
markers for dyslipidemia and oxidative stress is, however,
complex, and the contribution of these factors, separate or in
combination to the onset and degree of vascular dysfunction
measured in various vascular beds, should be assessed in future
research.
It is well known that insulin resistance plays an important
role in the development of endothelial dysfunction through
reduced production of NO31 and accelerated atherosclerosis in
IGT.32 Indeed, our IGT cohort demonstrated signs of early
atherosclerotic changes as measured by increased IMT at the
carotid level. This observation is in accordance with previous
results,33,34 and, in the light of all the other reported changes,
TABLE 3. Average Retinal Arterial and Venous Measures for Both
Groups
NGT (n ¼ 30) IGT (n ¼ 30) P Value
Artery
AD, lM 123.94 (112.85–133.77) 121.61 (96.91–174.28) 0.501
BDF, AU 5.14 (3.47–6.44) 6.42 (1.57–13.16)* 0.026
MD, % 5.05 (3.18–6.37) 5.48 (1.17–10.3) 0.433
MDRT, s 18.4 (13.3–22.7) 21.4 (10.7–37.0)* 0.032
MC, % 3.24 (1.84–4.29) 2.96 (0.45–6.48) 0.546
MCRT, s 20.1 (17.3–23.3) 19.7 (8.3–29.0) 0.691
DA, % 8.27 (5.99–9.73) 8.44 (2.19–16.47) 0.820
bFR, % 3.13 (1.48–4.75) 2.01 (5.57 to 7.17)* 0.045
Vein
AD, AU 155.75 (142.16–170.29) 159.29 (124.70–202.27) 0.468
BDF, AU 4.03 (2.54–4.96) 4.66 (2.04–9.89) 0.150
MD, % 5.71 (4.09–6.54) 5.92 (1.61–12.08) 0.704
MDRT, s 19.5 (17.0–22.0) 21.7 (12.0–31.7) 0.053
MC, % 1.43 (0.40–1.84) 2.01 (0.95–10.15) 0.114
MCRT, s 21.9 (19.3–25.3) 20.3 (7.0–29.3) 0.149
DA, % 7.14 (4.90–8.54) 7.83 (3.12–13.09) 0.290
bFR, % 3.12 (1.57–4.30) 3.14 (1.92 to 10.76) 0.975
Measures were corrected for age, sex, weight, BP, and circulating
serum markers. AD, absolute diameter; AU, arbitrary units; DA, dilation
amplitude; MCRT, reaction time to maximum constriction post flicker;
MD, maximum dilation; MDRT, reaction time to reach maximum
diameter to flicker stimulation.
* Significant differences indicated in bold (ANCOVA, P < 0.05).
FIGURE 1. Arterial MDRT for each of the three flicker cycles when
corrected for confounding variables (anthropometric: BP, and circulat-
ing markers: glucose, TG, TG:HDL) in the IGT group as compared to
NGT controls. Bars: average MDRT for each individual flicker cycle.
Error bars: SD of mean. Significant differences indicated in the first and
second flicker cycles as shown by the P values.
FIGURE 2. Arterial bFR when corrected for confounding variables for
each of the three flicker cycles for the IGT group as compared to NGT
controls. Bars: average bFR for each individual flicker cycle. Error
bars: SD of mean. Post hoc analysis of re-ANOVA showed a significant
reduction in bFR for the second flicker cycle.
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it possibly emphasizes the necessity of early cardiovascular
screening and intervention in prediabetes status including IGT.
An important finding of the present study was the presence
of impaired retinal vessel function to flicker (greater fluctua-
tions in arterial BDF, increased MDRT, and a reduced bFR), as
assessed by the DVA. Previous studies showing an increased
risk for diabetic retinopathy in IGT,35,36 have included
individuals suffering from hypertension, which could have
acted as a possible confounding factor.37 Moreover, the
observed changes were structural only and associated with
standard static fundus assessment, and to date, there is no
research showing preclinical functional retinal vascular chang-
es in subjects with IGT. Our study reported such changes for
the first time and although the precise mechanisms behind our
results need further elucidation, we can formulate some
hypotheses. For instance, there is some evidence to suggest
that an increased MDRT could be the result of either early
atherosclerosis, increased arterial stiffness, or reduced NO
bioavailability to peripheral tissues.7 Indeed, we have already
shown that all these mechanisms could be implicated in our
observed macrovascular changes; therefore, it is not unreason-
able to presume that similar relationships also occur at the
microvascular level including retinal microcirculation.
We also observed a higher fluctuation in retinal arterial BDF
with IGT status. BDF is a parameter, which although
recognized, is not commonly reported in the literature. It is
reported to demonstrate the effect of spontaneous variations in
vessel diameter that occur under normal resting conditions to
flicker light.38 Tentative links have been made in previous
studies between the occurrence of increased arterial diameter
fluctuations and the presence of vascular disturbance in both
smokers and vasospastic subjects19,39,40 and between in-
creased retinal venous diameters and the presence of retinal
ischemia and hypoxia.41,42 On this basis, it could be
hypothesized that the increased BDF identified in our IGT
patients may represent an indicator that common alterations in
retinal vascular function may exist in these individuals, perhaps
related to an increased variation in vascular tone or compli-
ance. Indeed, it is important to emphasize here that in our IGT
sample there was a correlation between signs of retinal
vascular dysfunction and plasma lipid levels, possibly suggest-
ing that dyslipidemia itself could have a direct influence on the
retinal vascular response as assessed by the DVA.7
All the above hypotheses, however, would require further
clarification and research. Nevertheless, another interesting
observation was that our IGT individuals showed a correlation
between abnormal retinal vascular reactivity and the validated
measure of systemic endothelial dysfunction (FMD). This
relationship could suggest that, although the macro- and
FIGURE 3. Lipid level and arterial BDF multivariate correlations in IGTs. Positive Spearman correlations for BDF against total cholesterol:HDL-C (r¼
0.541; P¼ 0.003) and a negative correlation with arterial BDF against HDL-C (r ¼0.5222; P ¼ 0.004).
FIGURE 4. Negative average arterial MDRT multivariate correlation
with brachial artery FMD in the IGT group (Spearman, r¼0.4546, P¼
0.017).
TABLE 4. Average Brachial Artery Reactivity as Means of Systemic
Vascular Endothelial Function between Both Groups
NGT (n ¼ 30) IGT (n ¼ 30) P Value
Brachial artery
Baseline diameter,
mm
4.04 (3.34–4.61) 4.53 (3.94–4.91)* 0.015
Peak diameter,
mm
4.40 (3.63–5.00) 4.72 (4.26–5.26) 0.119
FMD, % 8.61 (2.98–10.65) 5.50 (2.16–8.51)* 0.026
GTN
Peak diameter,
mm
5.02 (4.31–5.56) 5.27 (4.67–5.94) 0.307
GID, % 25.20 (17.35–31.69) 16.28 (14.16–19.27)* 0.012
Reactivity was corrected for age, sex, weight, BP, and circulating
serum markers. Values quoted in mean (IQR). GID, GTN-induced
dilation.
* Significant differences indicated in bold (ANCOVA, P < 0.05).
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microvascular beds’ functions are governed by different
physiological mechanisms, the pathologic changes associated
with the IGT state could affect all circulatory beds in a similar
manner. Indeed, it is well known that vascular pathologies
occurring in a given tissue or organ are not isolated, and both
the initiation and risk for further vascular dysfunction are
triggered by common mechanisms acting similarly at both
macro- and microcirculation levels.43 This is particularly
important in prediabetes and diabetes in which generalized
endothelial dysfunction can be induced by a combination of
pathologic changes including dyslipidemia, hypertension, IR,
and high levels of ROS, all mentioned above and measured in
the present research.
The pilot design of the present study could be perceived as
a limitation. The cross-sectional design of the study with a
small cohort can therefore represent a drawback. The authors
also recognize that future work would also need to incorporate
further biochemical analyses, including HbA1c and fasting
insulin levels, liver and kidney function tests, and hematology
profiles, in order to best understand the glycemic and vascular
function status at the time of diagnosis. Furthermore, the
influences of other nondietary and social factors (including
exercise) should be included in future work.
Nevertheless, the significant differences observed between
those with IGT and NGT would suggest that early changes in
vascular function can be seen in such individuals at both
macro- and microcirculatory levels. In addition, the relation-
ship between functional macro- and microvascular parameters,
observed retinal microcirculatory changes, and established
CVD risk markers emphasizes the importance of early vascular
screening in IGT subjects. Retinal vascular imaging could
emerge as a possible future option for individual risk
stratification in diseased patients44,45 but also in individuals
at risk for metabolic and cardiovascular pathologies.
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